Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer

Shoji Nakamori, Wakio Endo, Hiroki Ozato, Takashi Shibata, Yutaka Takeda, Ken Tohno, Yasunori Hasuike, Seizo Masutani, Takashi Morimoto, Yuichirou Doki, Masaki Mori, Morito Monden

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Our objective was to evaluate the efficacy and toxicity of the pre-administration of UFT (uracil/tegafur: prodrug of 5-FU) and GEM combination therapy for unresectable/recurrent pancreatic cancer in the outpatient setting. UFT (250 mg/m2/day) was orally administered from day 1 through day 6 and from day 8 through 13, and GEM (800 mg/m2, div/30min) was administered on day 7 and 14, with a one-week rest every 3 weeks based on results of the previous phase I study. Thirty-six pts (24 male, 12 female) were enrolled (median age, 63.8 yrs). There were 8 partial responses (25%). Eighteen pts (56%) had stable disease, and 6 pts (19%) had a progression. The median survival time was 7.0 months (range 1.5-66). Grade 3 toxicities were leucopenia (17%), thrombocytopenia (3%), nausea (3%), and liver dysfunctions (3%). There were no Grade 4 toxicities. Pre-administered UFT plus GM is a promising treatment for unresectable/recurrent pancreatic cancer in the outpatient setting.

Original languageEnglish
Pages (from-to)789-792
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number5
Publication statusPublished - May 15 2011

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this